Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Otolaryngology | 44 | 2023 | 645 | 11.160 |
Why?
|
Rhinitis | 64 | 2023 | 691 | 8.280 |
Why?
|
Sinusitis | 69 | 2023 | 923 | 8.180 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 13 | 2020 | 312 | 2.790 |
Why?
|
Nasal Polyps | 12 | 2023 | 360 | 2.690 |
Why?
|
Endoscopy | 30 | 2023 | 1784 | 2.550 |
Why?
|
Internship and Residency | 23 | 2023 | 5787 | 2.420 |
Why?
|
Paranasal Sinus Neoplasms | 10 | 2024 | 234 | 2.300 |
Why?
|
Paranasal Sinus Diseases | 8 | 2020 | 116 | 2.210 |
Why?
|
Turbinates | 8 | 2019 | 68 | 1.930 |
Why?
|
Paranasal Sinuses | 13 | 2023 | 250 | 1.750 |
Why?
|
Equipment and Supplies | 3 | 2019 | 281 | 1.660 |
Why?
|
Device Approval | 3 | 2019 | 163 | 1.640 |
Why?
|
Nasal Obstruction | 6 | 2019 | 151 | 1.620 |
Why?
|
Education, Medical, Graduate | 13 | 2023 | 2291 | 1.490 |
Why?
|
Personnel Selection | 5 | 2023 | 189 | 1.490 |
Why?
|
Maxillary Sinus | 4 | 2023 | 180 | 1.480 |
Why?
|
Chronic Disease | 64 | 2023 | 9147 | 1.300 |
Why?
|
Maxillary Sinusitis | 3 | 2023 | 39 | 1.290 |
Why?
|
Medicare | 8 | 2023 | 6566 | 1.030 |
Why?
|
Epistaxis | 2 | 2017 | 111 | 1.000 |
Why?
|
Nose Neoplasms | 3 | 2023 | 246 | 0.990 |
Why?
|
Efficiency | 5 | 2021 | 462 | 0.990 |
Why?
|
United States Food and Drug Administration | 5 | 2023 | 1583 | 0.980 |
Why?
|
Enophthalmos | 2 | 2015 | 34 | 0.930 |
Why?
|
Quality of Life | 32 | 2024 | 12805 | 0.890 |
Why?
|
Equipment Safety | 3 | 2018 | 264 | 0.880 |
Why?
|
Adrenal Cortex Hormones | 11 | 2021 | 1854 | 0.880 |
Why?
|
General Surgery | 3 | 2023 | 1636 | 0.820 |
Why?
|
Otorhinolaryngologic Diseases | 2 | 2020 | 90 | 0.820 |
Why?
|
Cross-Sectional Studies | 37 | 2023 | 25043 | 0.780 |
Why?
|
Pain, Postoperative | 3 | 2020 | 1640 | 0.780 |
Why?
|
Fees, Medical | 1 | 2021 | 117 | 0.740 |
Why?
|
Hypersensitivity | 4 | 2024 | 1102 | 0.740 |
Why?
|
Emergency Service, Hospital | 10 | 2020 | 7659 | 0.690 |
Why?
|
Analgesics, Opioid | 3 | 2020 | 3674 | 0.680 |
Why?
|
Clinical Competence | 9 | 2023 | 4687 | 0.670 |
Why?
|
Capital Financing | 1 | 2019 | 58 | 0.670 |
Why?
|
Economics, Hospital | 1 | 2021 | 213 | 0.660 |
Why?
|
Health Care Sector | 2 | 2017 | 194 | 0.660 |
Why?
|
Physicians, Women | 3 | 2020 | 486 | 0.650 |
Why?
|
Bibliometrics | 5 | 2021 | 339 | 0.650 |
Why?
|
United States | 40 | 2023 | 69867 | 0.630 |
Why?
|
Esthesioneuroblastoma, Olfactory | 2 | 2023 | 56 | 0.620 |
Why?
|
Retrospective Studies | 46 | 2024 | 77426 | 0.610 |
Why?
|
Humans | 166 | 2024 | 744220 | 0.610 |
Why?
|
Off-Label Use | 1 | 2019 | 169 | 0.610 |
Why?
|
Investments | 1 | 2019 | 143 | 0.600 |
Why?
|
Financing, Government | 1 | 2021 | 468 | 0.600 |
Why?
|
Neck Injuries | 2 | 2019 | 152 | 0.590 |
Why?
|
Career Choice | 4 | 2021 | 744 | 0.590 |
Why?
|
Adenoidectomy | 1 | 2018 | 159 | 0.590 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2020 | 365 | 0.580 |
Why?
|
Career Mobility | 2 | 2018 | 262 | 0.580 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 397 | 0.570 |
Why?
|
Hemostatic Techniques | 1 | 2017 | 116 | 0.560 |
Why?
|
Papilloma, Inverted | 1 | 2015 | 16 | 0.540 |
Why?
|
Telemedicine | 3 | 2023 | 2872 | 0.540 |
Why?
|
Tonsillectomy | 1 | 2018 | 254 | 0.530 |
Why?
|
Professional Autonomy | 3 | 2021 | 177 | 0.530 |
Why?
|
Faculty, Medical | 3 | 2018 | 1181 | 0.520 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2020 | 454 | 0.510 |
Why?
|
Nasal Cavity | 4 | 2024 | 313 | 0.510 |
Why?
|
Invasive Pulmonary Aspergillosis | 1 | 2014 | 15 | 0.510 |
Why?
|
Male | 104 | 2023 | 350027 | 0.490 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2014 | 40 | 0.470 |
Why?
|
Educational Measurement | 4 | 2023 | 1209 | 0.470 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3158 | 0.470 |
Why?
|
Middle Aged | 81 | 2023 | 213367 | 0.470 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2017 | 437 | 0.470 |
Why?
|
Severity of Illness Index | 14 | 2021 | 15538 | 0.460 |
Why?
|
Skull Fracture, Basilar | 1 | 2012 | 6 | 0.450 |
Why?
|
Orbital Diseases | 2 | 2015 | 181 | 0.450 |
Why?
|
Pituitary Neoplasms | 1 | 2022 | 1346 | 0.450 |
Why?
|
Female | 101 | 2023 | 380197 | 0.440 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2017 | 430 | 0.440 |
Why?
|
Models, Psychological | 1 | 2017 | 811 | 0.430 |
Why?
|
Professional Competence | 1 | 2016 | 448 | 0.430 |
Why?
|
Adult | 70 | 2023 | 214035 | 0.430 |
Why?
|
Drug Prescriptions | 2 | 2020 | 1637 | 0.430 |
Why?
|
Biological Products | 1 | 2021 | 860 | 0.430 |
Why?
|
Cerebrospinal Fluid Rhinorrhea | 1 | 2012 | 80 | 0.430 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 670 | 0.430 |
Why?
|
Budesonide | 3 | 2023 | 154 | 0.420 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2021 | 450 | 0.420 |
Why?
|
Nose | 4 | 2024 | 509 | 0.420 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2021 | 4033 | 0.420 |
Why?
|
Orbit | 1 | 2015 | 426 | 0.410 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2012 | 61 | 0.410 |
Why?
|
Health Care Reform | 1 | 2021 | 1261 | 0.400 |
Why?
|
Income | 1 | 2020 | 1913 | 0.390 |
Why?
|
Models, Educational | 1 | 2014 | 377 | 0.390 |
Why?
|
Skull Base | 2 | 2021 | 306 | 0.390 |
Why?
|
Sex Factors | 9 | 2021 | 10396 | 0.380 |
Why?
|
Hospital Costs | 2 | 2019 | 984 | 0.380 |
Why?
|
Head and Neck Neoplasms | 4 | 2024 | 2732 | 0.380 |
Why?
|
Seasons | 2 | 2019 | 1494 | 0.370 |
Why?
|
Aged | 47 | 2023 | 163253 | 0.370 |
Why?
|
Chordoma | 1 | 2013 | 359 | 0.370 |
Why?
|
Drug Approval | 1 | 2017 | 741 | 0.370 |
Why?
|
Rhinoplasty | 3 | 2019 | 226 | 0.360 |
Why?
|
Craniocerebral Trauma | 1 | 2014 | 482 | 0.360 |
Why?
|
Prescription Drugs | 1 | 2017 | 595 | 0.350 |
Why?
|
Iatrogenic Disease | 1 | 2012 | 547 | 0.340 |
Why?
|
Tomography, X-Ray Computed | 11 | 2021 | 20123 | 0.340 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 3023 | 0.330 |
Why?
|
Nose Diseases | 2 | 2020 | 79 | 0.330 |
Why?
|
Survival Rate | 2 | 2021 | 12781 | 0.330 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3132 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3239 | 0.310 |
Why?
|
Cystic Fibrosis | 1 | 2017 | 1178 | 0.310 |
Why?
|
Publishing | 1 | 2015 | 833 | 0.310 |
Why?
|
Disease Management | 1 | 2018 | 2458 | 0.300 |
Why?
|
Prospective Studies | 31 | 2023 | 53280 | 0.300 |
Why?
|
Authorship | 2 | 2021 | 271 | 0.300 |
Why?
|
Biomedical Research | 3 | 2021 | 3311 | 0.290 |
Why?
|
Anti-Bacterial Agents | 11 | 2020 | 7179 | 0.280 |
Why?
|
Oropharynx | 1 | 2007 | 127 | 0.280 |
Why?
|
Asthma | 9 | 2023 | 6011 | 0.280 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 9230 | 0.280 |
Why?
|
Empathy | 1 | 2011 | 472 | 0.280 |
Why?
|
Dilatation | 2 | 2017 | 291 | 0.280 |
Why?
|
Papillomavirus Infections | 2 | 2017 | 1587 | 0.270 |
Why?
|
Depression | 7 | 2019 | 7767 | 0.270 |
Why?
|
Surgery, Computer-Assisted | 2 | 2022 | 1018 | 0.270 |
Why?
|
Postoperative Complications | 6 | 2018 | 15294 | 0.260 |
Why?
|
Natural Orifice Endoscopic Surgery | 2 | 2019 | 118 | 0.260 |
Why?
|
Speech, Esophageal | 1 | 2004 | 10 | 0.250 |
Why?
|
Ear Diseases | 2 | 2017 | 170 | 0.250 |
Why?
|
Pharynx | 2 | 2023 | 413 | 0.250 |
Why?
|
Pharyngectomy | 1 | 2004 | 45 | 0.240 |
Why?
|
Dacryocystorhinostomy | 2 | 2016 | 72 | 0.240 |
Why?
|
Nasal Lavage | 1 | 2023 | 11 | 0.240 |
Why?
|
Needs Assessment | 2 | 2023 | 1147 | 0.230 |
Why?
|
Health Status | 1 | 2017 | 4034 | 0.230 |
Why?
|
Interpersonal Relations | 1 | 2011 | 1424 | 0.220 |
Why?
|
Foreign Bodies | 1 | 2007 | 399 | 0.220 |
Why?
|
Rhinitis, Allergic, Perennial | 2 | 2013 | 57 | 0.210 |
Why?
|
Carcinoma | 1 | 2014 | 2375 | 0.210 |
Why?
|
Rhinitis, Allergic, Seasonal | 2 | 2013 | 99 | 0.210 |
Why?
|
Laryngectomy | 1 | 2004 | 248 | 0.210 |
Why?
|
Toll-Like Receptor 3 | 2 | 2015 | 91 | 0.210 |
Why?
|
Operating Rooms | 2 | 2021 | 815 | 0.200 |
Why?
|
Students, Medical | 1 | 2014 | 1862 | 0.200 |
Why?
|
Neurosurgical Procedures | 1 | 2012 | 2003 | 0.200 |
Why?
|
Endoscopes | 1 | 2022 | 175 | 0.190 |
Why?
|
Pulpitis | 1 | 2021 | 26 | 0.190 |
Why?
|
Aerosols | 2 | 2020 | 623 | 0.190 |
Why?
|
Nasal Septum | 2 | 2019 | 127 | 0.190 |
Why?
|
Skull Base Neoplasms | 1 | 2024 | 284 | 0.180 |
Why?
|
Pandemics | 5 | 2023 | 8387 | 0.180 |
Why?
|
Papillomaviridae | 2 | 2017 | 1119 | 0.170 |
Why?
|
Insurance Coverage | 3 | 2021 | 1901 | 0.170 |
Why?
|
Physician Executives | 1 | 2020 | 128 | 0.170 |
Why?
|
Nasal Mucosa | 2 | 2015 | 373 | 0.170 |
Why?
|
Young Adult | 15 | 2019 | 56436 | 0.170 |
Why?
|
Research Support as Topic | 2 | 2021 | 704 | 0.170 |
Why?
|
Intubation, Intratracheal | 1 | 2007 | 1357 | 0.170 |
Why?
|
Treatment Outcome | 17 | 2024 | 63119 | 0.170 |
Why?
|
Vasculitis | 1 | 2023 | 521 | 0.170 |
Why?
|
Avoidance Learning | 1 | 2020 | 233 | 0.170 |
Why?
|
Arkansas | 1 | 2018 | 52 | 0.170 |
Why?
|
Job Application | 1 | 2018 | 39 | 0.160 |
Why?
|
Periodicals as Topic | 2 | 2020 | 1432 | 0.160 |
Why?
|
Mucociliary Clearance | 1 | 2018 | 67 | 0.160 |
Why?
|
Administration, Oral | 4 | 2019 | 3913 | 0.160 |
Why?
|
Fractures, Closed | 1 | 2019 | 88 | 0.160 |
Why?
|
Asthma, Aspirin-Induced | 1 | 2021 | 182 | 0.160 |
Why?
|
Anti-Asthmatic Agents | 2 | 2020 | 536 | 0.160 |
Why?
|
Fractures, Open | 1 | 2019 | 101 | 0.160 |
Why?
|
Tooth Diseases | 1 | 2018 | 77 | 0.150 |
Why?
|
Activities of Daily Living | 4 | 2020 | 2420 | 0.150 |
Why?
|
Cockroaches | 1 | 2017 | 96 | 0.150 |
Why?
|
Child | 13 | 2021 | 77679 | 0.150 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39045 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 252 | 0.150 |
Why?
|
Physician-Patient Relations | 1 | 2011 | 3227 | 0.150 |
Why?
|
Publications | 1 | 2019 | 195 | 0.150 |
Why?
|
Specialties, Surgical | 1 | 2022 | 391 | 0.150 |
Why?
|
Self Report | 2 | 2018 | 3558 | 0.140 |
Why?
|
Sodium Chloride | 1 | 2019 | 625 | 0.140 |
Why?
|
Incidence | 4 | 2023 | 20945 | 0.140 |
Why?
|
Risk Assessment | 7 | 2020 | 23337 | 0.140 |
Why?
|
Personality | 1 | 2020 | 552 | 0.140 |
Why?
|
After-Hours Care | 1 | 2017 | 102 | 0.140 |
Why?
|
Child, Preschool | 9 | 2019 | 40992 | 0.140 |
Why?
|
Hypertrophy | 1 | 2018 | 569 | 0.140 |
Why?
|
Rheumatic Diseases | 1 | 2023 | 593 | 0.140 |
Why?
|
Absenteeism | 1 | 2018 | 250 | 0.140 |
Why?
|
Sick Leave | 1 | 2017 | 110 | 0.140 |
Why?
|
Massachusetts | 5 | 2015 | 8663 | 0.140 |
Why?
|
Curriculum | 2 | 2023 | 3604 | 0.130 |
Why?
|
Aged, 80 and over | 11 | 2019 | 57768 | 0.130 |
Why?
|
Antifungal Agents | 2 | 2017 | 730 | 0.130 |
Why?
|
Logistic Models | 3 | 2021 | 13409 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2020 | 764 | 0.130 |
Why?
|
Vulnerable Populations | 1 | 2021 | 686 | 0.130 |
Why?
|
Cohort Studies | 10 | 2018 | 40559 | 0.130 |
Why?
|
Nose Deformities, Acquired | 1 | 2015 | 44 | 0.130 |
Why?
|
Smoking | 3 | 2017 | 8986 | 0.130 |
Why?
|
Education | 1 | 2018 | 543 | 0.130 |
Why?
|
Diagnostic Techniques, Otological | 1 | 2015 | 12 | 0.130 |
Why?
|
Industry | 1 | 2017 | 365 | 0.130 |
Why?
|
Meningioma | 1 | 2024 | 1209 | 0.130 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8628 | 0.130 |
Why?
|
Comorbidity | 6 | 2020 | 10387 | 0.120 |
Why?
|
Prednisone | 1 | 2019 | 1575 | 0.120 |
Why?
|
Meningeal Neoplasms | 1 | 2024 | 1241 | 0.120 |
Why?
|
Acute Disease | 4 | 2019 | 7148 | 0.120 |
Why?
|
Physical Therapy Modalities | 1 | 2018 | 550 | 0.120 |
Why?
|
Mucormycosis | 1 | 2015 | 97 | 0.120 |
Why?
|
Peer Review, Research | 1 | 2017 | 329 | 0.120 |
Why?
|
Eye Infections, Fungal | 1 | 2015 | 110 | 0.120 |
Why?
|
Consensus | 3 | 2021 | 2958 | 0.120 |
Why?
|
Telephone | 1 | 2017 | 617 | 0.120 |
Why?
|
Airway Remodeling | 1 | 2015 | 132 | 0.120 |
Why?
|
Larynx | 1 | 2019 | 494 | 0.120 |
Why?
|
Judgment | 1 | 2016 | 281 | 0.120 |
Why?
|
Activins | 1 | 2015 | 208 | 0.120 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 933 | 0.120 |
Why?
|
Frontal Sinus | 1 | 2013 | 50 | 0.120 |
Why?
|
Problem Solving | 1 | 2016 | 440 | 0.110 |
Why?
|
Aspergillosis | 1 | 2015 | 235 | 0.110 |
Why?
|
Prosthesis Implantation | 1 | 2018 | 642 | 0.110 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2013 | 48 | 0.110 |
Why?
|
Neoplasm Staging | 2 | 2021 | 11007 | 0.110 |
Why?
|
Intubation | 1 | 2013 | 141 | 0.110 |
Why?
|
Adolescent | 10 | 2019 | 85759 | 0.110 |
Why?
|
Cautery | 1 | 2013 | 72 | 0.110 |
Why?
|
Nasolacrimal Duct | 1 | 2013 | 74 | 0.110 |
Why?
|
Algorithms | 1 | 2013 | 13885 | 0.110 |
Why?
|
Pilot Projects | 2 | 2019 | 8321 | 0.110 |
Why?
|
Ligation | 1 | 2013 | 453 | 0.110 |
Why?
|
Steroids | 1 | 2017 | 931 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2021 | 1401 | 0.100 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2012 | 50 | 0.100 |
Why?
|
Organ Culture Techniques | 1 | 2014 | 813 | 0.100 |
Why?
|
Catheterization | 1 | 2017 | 1469 | 0.100 |
Why?
|
Disease Progression | 6 | 2018 | 13280 | 0.100 |
Why?
|
Societies, Medical | 2 | 2021 | 3741 | 0.100 |
Why?
|
Bandages | 1 | 2013 | 266 | 0.100 |
Why?
|
Risk Factors | 10 | 2020 | 72280 | 0.100 |
Why?
|
Accreditation | 1 | 2014 | 450 | 0.100 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2015 | 644 | 0.100 |
Why?
|
Patient Selection | 2 | 2018 | 4216 | 0.100 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2136 | 0.100 |
Why?
|
Odds Ratio | 3 | 2018 | 9849 | 0.100 |
Why?
|
Surgical Flaps | 2 | 2013 | 1640 | 0.100 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 7908 | 0.100 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12244 | 0.100 |
Why?
|
Ophthalmology | 1 | 2017 | 508 | 0.090 |
Why?
|
Headache | 1 | 2018 | 1226 | 0.090 |
Why?
|
Infant | 4 | 2016 | 35129 | 0.090 |
Why?
|
Sex Characteristics | 1 | 2021 | 2586 | 0.090 |
Why?
|
Cochlear Implantation | 1 | 2014 | 310 | 0.090 |
Why?
|
Health Care Costs | 2 | 2014 | 3209 | 0.090 |
Why?
|
Organ Size | 1 | 2015 | 2252 | 0.090 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 1076 | 0.090 |
Why?
|
Education, Medical, Continuing | 1 | 2015 | 840 | 0.090 |
Why?
|
Patient Preference | 1 | 2017 | 887 | 0.090 |
Why?
|
Prognosis | 5 | 2019 | 29050 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7784 | 0.090 |
Why?
|
Workload | 1 | 2015 | 850 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 969 | 0.080 |
Why?
|
Complex Mixtures | 1 | 2008 | 28 | 0.080 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 5396 | 0.080 |
Why?
|
Liposarcoma | 1 | 2012 | 333 | 0.080 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 1411 | 0.080 |
Why?
|
Allergens | 1 | 2016 | 1320 | 0.080 |
Why?
|
Bone Transplantation | 1 | 2013 | 907 | 0.080 |
Why?
|
Databases, Factual | 3 | 2019 | 7730 | 0.080 |
Why?
|
SEER Program | 1 | 2013 | 1508 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6461 | 0.080 |
Why?
|
Emotions | 1 | 2020 | 2659 | 0.080 |
Why?
|
Chemokine CCL5 | 1 | 2008 | 209 | 0.080 |
Why?
|
Administration, Intranasal | 2 | 2019 | 446 | 0.080 |
Why?
|
Patient Satisfaction | 4 | 2014 | 3395 | 0.080 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6893 | 0.080 |
Why?
|
Hematoma | 1 | 2013 | 758 | 0.080 |
Why?
|
Gastroesophageal Reflux | 1 | 2015 | 782 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 12961 | 0.080 |
Why?
|
Survival Analysis | 3 | 2019 | 10250 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6535 | 0.080 |
Why?
|
Medicaid | 1 | 2021 | 2736 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2021 | 21752 | 0.080 |
Why?
|
Risk | 2 | 2017 | 9685 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2016 | 6367 | 0.080 |
Why?
|
Biocompatible Materials | 1 | 2016 | 1736 | 0.070 |
Why?
|
Patient Admission | 1 | 2015 | 1380 | 0.070 |
Why?
|
Educational Status | 1 | 2015 | 2539 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14726 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12355 | 0.070 |
Why?
|
Cadaver | 2 | 2020 | 1337 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3614 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15070 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1255 | 0.070 |
Why?
|
Smoking Cessation | 1 | 2017 | 2071 | 0.060 |
Why?
|
Syndrome | 1 | 2011 | 3250 | 0.060 |
Why?
|
Software | 2 | 2022 | 4442 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5316 | 0.060 |
Why?
|
Health Surveys | 1 | 2014 | 4037 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3746 | 0.060 |
Why?
|
Attitude | 2 | 2019 | 774 | 0.060 |
Why?
|
Biopsy | 2 | 2015 | 6757 | 0.060 |
Why?
|
Boston | 1 | 2016 | 9311 | 0.060 |
Why?
|
Perception | 2 | 2020 | 1198 | 0.060 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1916 | 0.050 |
Why?
|
Sex Distribution | 2 | 2020 | 2297 | 0.050 |
Why?
|
Tobacco Smoke Pollution | 1 | 2008 | 815 | 0.050 |
Why?
|
Jejunum | 1 | 2004 | 480 | 0.050 |
Why?
|
Linear Models | 3 | 2019 | 5953 | 0.050 |
Why?
|
Propensity Score | 2 | 2019 | 1781 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4044 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 9960 | 0.050 |
Why?
|
Viridans Streptococci | 1 | 2021 | 15 | 0.050 |
Why?
|
Stents | 1 | 2013 | 3280 | 0.050 |
Why?
|
Morbidity | 2 | 2019 | 1769 | 0.050 |
Why?
|
Time Factors | 4 | 2019 | 40063 | 0.050 |
Why?
|
Leadership | 2 | 2021 | 1357 | 0.050 |
Why?
|
Gastric Mucosa | 1 | 2004 | 599 | 0.050 |
Why?
|
Research Design | 1 | 2017 | 5987 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2014 | 19227 | 0.050 |
Why?
|
Academic Medical Centers | 3 | 2018 | 2759 | 0.050 |
Why?
|
Sneezing | 1 | 2020 | 17 | 0.050 |
Why?
|
Tracheostomy | 1 | 2004 | 400 | 0.050 |
Why?
|
ROC Curve | 2 | 2018 | 3527 | 0.050 |
Why?
|
Governing Board | 1 | 2020 | 53 | 0.050 |
Why?
|
Nasal Sprays | 1 | 2019 | 18 | 0.040 |
Why?
|
Drug Implants | 1 | 2020 | 243 | 0.040 |
Why?
|
Periapical Abscess | 1 | 2018 | 16 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2022 | 359 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 127 | 0.040 |
Why?
|
Absorbable Implants | 1 | 2020 | 342 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 780 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15226 | 0.040 |
Why?
|
Leukotriene Antagonists | 1 | 2017 | 127 | 0.040 |
Why?
|
Current Procedural Terminology | 1 | 2017 | 92 | 0.040 |
Why?
|
Faculty | 1 | 2020 | 386 | 0.040 |
Why?
|
Tooth | 1 | 2018 | 207 | 0.040 |
Why?
|
Medicare Part B | 1 | 2017 | 108 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2008 | 3690 | 0.030 |
Why?
|
Particle Size | 1 | 2020 | 1642 | 0.030 |
Why?
|
Mucorales | 1 | 2015 | 33 | 0.030 |
Why?
|
Aspergillus | 1 | 2015 | 85 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2017 | 977 | 0.030 |
Why?
|
Hyperbaric Oxygenation | 1 | 2015 | 163 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2019 | 1770 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1841 | 0.030 |
Why?
|
Length of Stay | 2 | 2019 | 6308 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 2016 | 389 | 0.030 |
Why?
|
Private Practice | 1 | 2014 | 154 | 0.030 |
Why?
|
Debridement | 1 | 2015 | 492 | 0.030 |
Why?
|
Conflict of Interest | 1 | 2017 | 543 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 29784 | 0.030 |
Why?
|
Hospitals, University | 1 | 2014 | 571 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2015 | 940 | 0.030 |
Why?
|
Radiography | 2 | 2013 | 7022 | 0.030 |
Why?
|
Models, Organizational | 1 | 2014 | 574 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
Phenotype | 2 | 2019 | 16365 | 0.020 |
Why?
|
Triage | 1 | 2017 | 976 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2949 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 12075 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2014 | 603 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 159 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2486 | 0.020 |
Why?
|
Aspirin | 1 | 2021 | 3282 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1682 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2453 | 0.020 |
Why?
|
Chemokine CCL7 | 1 | 2008 | 27 | 0.020 |
Why?
|
Immunochemistry | 1 | 2008 | 124 | 0.020 |
Why?
|
beta-Defensins | 1 | 2008 | 57 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2903 | 0.020 |
Why?
|
Social Class | 1 | 2017 | 1999 | 0.020 |
Why?
|
Patients | 1 | 2015 | 900 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2017 | 1766 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3584 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1683 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2715 | 0.020 |
Why?
|
Medication Adherence | 1 | 2019 | 2062 | 0.020 |
Why?
|
RNA, Double-Stranded | 1 | 2008 | 290 | 0.020 |
Why?
|
Interferon-beta | 1 | 2008 | 323 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8343 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2008 | 690 | 0.020 |
Why?
|
Interferons | 1 | 2008 | 706 | 0.020 |
Why?
|
Data Collection | 1 | 2014 | 3340 | 0.020 |
Why?
|
Interleukins | 1 | 2008 | 791 | 0.010 |
Why?
|
Neurons | 1 | 2023 | 9335 | 0.010 |
Why?
|
Graft Survival | 1 | 2013 | 3740 | 0.010 |
Why?
|
Interleukin-1beta | 1 | 2008 | 972 | 0.010 |
Why?
|
Pain | 1 | 2017 | 4987 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 13990 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2008 | 2216 | 0.010 |
Why?
|
Graft Rejection | 1 | 2013 | 4399 | 0.010 |
Why?
|
Computer Simulation | 1 | 2014 | 6196 | 0.010 |
Why?
|
Pediatrics | 1 | 2014 | 3469 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19907 | 0.010 |
Why?
|
Hospitalization | 1 | 2019 | 10262 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2008 | 3201 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168788 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4419 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81178 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2015 | 25618 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2008 | 13036 | 0.010 |
Why?
|